Search Results - Sandrine I. Samson

A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries by Margaret Haugh, Viviane Gresset-Bourgeois, Bérengère Macabeo, Anne Woods, Sandrine I. Samson

Connect to this object online.

Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years by J. Kevin Yin, Stephanie Pepin, Robertus van Aalst, Matthew M. Loiacono, Sandrine I. Samson

Connect to this object online.

Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis by Sandrine I. Samson, Phillip S. Leventhal, Camille Salamand, Ya Meng, Bruce T. Seet, Victoria Landolfi, David Greenberg, Rosalind Hollingsworth

Connect to this object online.

Quadrivalent inactivated influenza vaccine (VaxigripTetra™) by Viviane Gresset-Bourgeois, Phillip S. Leventhal, Stéphanie Pepin, Rosalind Hollingsworth, Marie-Pierre, Iris De Bruijn, Sandrine I. Samson

Connect to this object online.

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies by Xiaoqiang Liu, Juliana Park, Shengli Xia, Bin Liang, Shuangmin Yang, Yanxia Wang, Olga Syrkina, Nathalie Lavis, Shuzhen Liu, Chenyan Zhao, Jian Ding, Jieqiong Hu, Sandrine I. Samson, Iris A. de Bruijn, for the FSQ01 and FSQ02 Study Groups

Connect to this object online.